$NRXP
NRX Pharmaceuticals, Inc.

2024 Q2 Form 10-Q Financial Statement

#000155837024008144 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.246M $4.250M $5.785M
YoY Change 4.45% -26.53% -43.41%
% of Gross Profit
Research & Development $2.804M $1.748M $3.650M
YoY Change -27.6% -52.11% -33.43%
% of Gross Profit
Depreciation & Amortization $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $7.050M $5.998M $9.435M
YoY Change -13.9% -36.43% -39.92%
Operating Profit -$7.050M -$5.998M -$9.435M
YoY Change -13.9% -36.43% -39.92%
Interest Expense $7.000K $230.0K $168.0K
YoY Change -95.17% 36.9% 5500.0%
% of Operating Profit
Other Income/Expense, Net -$847.0K -$530.0K -$1.604M
YoY Change 60.11% -66.96% -171.07%
Pretax Income -$7.897M -$6.528M -$11.04M
YoY Change -9.41% -40.86% -17.91%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.897M -$6.528M -$11.04M
YoY Change -9.41% -40.86% -17.91%
Net Earnings / Revenue
Basic Earnings Per Share -$0.75 -$0.74 -$0.16
Diluted Earnings Per Share -$0.75 -$0.74 -$0.16
COMMON SHARES
Basic Shares Outstanding 10.70M 95.70M 71.56M
Diluted Shares Outstanding 8.852M 67.45M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.898M $1.319M $16.51M
YoY Change -87.32% -92.01% -58.94%
Cash & Equivalents $1.900M $1.319M $16.51M
Short-Term Investments
Other Short-Term Assets $2.982M $128.0K $5.250M
YoY Change -38.12% -97.56% 55.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables $6.000K
Total Short-Term Assets $4.880M $3.347M $21.76M
YoY Change -75.34% -84.62% -50.08%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $384.0K $441.0K $24.00K
YoY Change 1728.57% 1737.5% 41.18%
Total Long-Term Assets $384.0K $441.0K $24.00K
YoY Change 1728.57% 1737.5% 41.18%
TOTAL ASSETS
Total Short-Term Assets $4.880M $3.347M $21.76M
Total Long-Term Assets $384.0K $441.0K $24.00K
Total Assets $5.264M $3.788M $21.78M
YoY Change -73.43% -82.61% -50.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.015M $6.265M $3.776M
YoY Change 127.44% 65.92% -12.41%
Accrued Expenses $5.555M $5.296M $5.054M
YoY Change -3.94% 4.79% 26.32%
Deferred Revenue
YoY Change
Short-Term Debt $943.0K $0.00 $0.00
YoY Change
Long-Term Debt Due $7.651M $6.779M $12.19M
YoY Change -39.72% -44.38% 2244.04%
Total Short-Term Liabilities $23.66M $18.86M $22.06M
YoY Change 4.59% -14.53% 85.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $23.66M $18.86M $22.06M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $23.66M $18.86M $22.06M
YoY Change 4.59% -14.53% 85.22%
SHAREHOLDERS EQUITY
Retained Earnings -$267.6M -$259.7M -$234.0M
YoY Change 10.22% 10.96% 18.99%
Common Stock $11.00K $10.00K $70.00K
YoY Change -86.25% -85.71% 4.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$18.39M -$15.07M -$284.0K
YoY Change
Total Liabilities & Shareholders Equity $5.264M $3.788M $21.78M
YoY Change -73.43% -82.61% -50.05%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$7.897M -$6.528M -$11.04M
YoY Change -9.41% -40.86% -17.91%
Depreciation, Depletion And Amortization $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities -$2.562M -$3.671M -$6.089M
YoY Change -67.2% -39.71% -41.34%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $4.000K
YoY Change -100.0% -100.0% -233.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$4.000K
YoY Change -100.0% -100.0% 33.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.141M 395.0K 2.545M
YoY Change -49.93% -84.48% -88.93%
NET CHANGE
Cash From Operating Activities -2.562M -3.671M -6.089M
Cash From Investing Activities 0.000 0.000 -4.000K
Cash From Financing Activities 3.141M 395.0K 2.545M
Net Change In Cash 579.0K -3.276M -3.548M
YoY Change -137.67% -7.67% -128.17%
FREE CASH FLOW
Cash From Operating Activities -$2.562M -$3.671M -$6.089M
Capital Expenditures $0.00 $0.00 $4.000K
Free Cash Flow -$2.562M -$3.671M -$6.093M
YoY Change -67.2% -39.75% -41.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8852286
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6647391
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001719406
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
NRX Pharmaceuticals, Inc.
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9772672
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8391940
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.66
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2024Q1 us-gaap Operating Cost And Expense Related Party Type Extensible Enumeration
OperatingCostAndExpenseRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpenseMember
CY2023Q1 us-gaap Operating Cost And Expense Related Party Type Extensible Enumeration
OperatingCostAndExpenseRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpenseMember
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38302
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2844431
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1201 Orange Street
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmington
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19801
CY2024Q1 dei City Area Code
CityAreaCode
484
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
254-6134
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10700609
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1319000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4595000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2028000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2289000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
3347000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
6884000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
441000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
431000
CY2024Q1 us-gaap Assets
Assets
3788000
CY2023Q4 us-gaap Assets
Assets
7315000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6265000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4632000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5296000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4714000
CY2024Q1 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
491000
CY2023Q4 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
524000
CY2024Q1 nrxp Convertible Notes Payable Accrued Interest
ConvertibleNotesPayableAccruedInterest
6779000
CY2023Q4 nrxp Convertible Notes Payable Accrued Interest
ConvertibleNotesPayableAccruedInterest
9161000
CY2024Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
26000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
17000
CY2024Q1 us-gaap Liabilities
Liabilities
18857000
CY2023Q4 us-gaap Liabilities
Liabilities
19048000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9772672
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8391940
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
10000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
244599000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
241406000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-259675000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-253147000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-15069000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11733000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3788000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7315000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1748000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3650000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4250000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5785000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
5998000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
9435000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5998000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9435000
CY2024Q1 us-gaap Interest Income Other
InterestIncomeOther
27000
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
156000
CY2024Q1 us-gaap Interest Expense
InterestExpense
230000
CY2024Q1 nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-318000
CY2023Q1 nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-1772000
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-9000
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
12000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-530000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1604000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6528000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11039000
CY2023Q1 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
-106000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
106000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-6528000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-10933000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.66
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8852286
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6647391
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11733000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
242000
CY2024Q1 nrxp Sale Of Stock And Warrants Issuance Costs
SaleOfStockAndWarrantsIssuanceCosts
481000
CY2024Q1 nrxp Common Stock And Warrants Issued Value New Issues
CommonStockAndWarrantsIssuedValueNewIssues
1344000
CY2024Q1 nrxp Number Of Shares To Be Issued
NumberOfSharesToBeIssued
270000
CY2024Q1 nrxp Common Stock And Warrants Issued In Private Placement Net Of Issuance Costs
CommonStockAndWarrantsIssuedInPrivatePlacementNetOfIssuanceCosts
1027000
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
400000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6528000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-15069000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7409000
CY2023Q1 nrxp Sale Of Stock And Warrants Issuance Costs
SaleOfStockAndWarrantsIssuanceCosts
351000
CY2023Q1 nrxp Common Stock And Warrants Issued Value New Issues
CommonStockAndWarrantsIssuedValueNewIssues
2545000
CY2023Q1 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
-106000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
695000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11039000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-284000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-6528000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-11039000
CY2024Q1 us-gaap Depreciation
Depreciation
1000
CY2023Q1 us-gaap Depreciation
Depreciation
1000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
242000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
695000
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
9000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-12000
CY2024Q1 nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-318000
CY2023Q1 nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-1772000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-250000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-491000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2091000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1698000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-54000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
305000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3671000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6089000
CY2023Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
4000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
CY2024Q1 nrxp Repayments Of Convertible Note
RepaymentsOfConvertibleNote
2155000
CY2024Q1 nrxp Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
1523000
CY2024Q1 nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
1027000
CY2023Q1 nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
2545000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
395000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2545000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3276000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3548000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4595000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20054000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1319000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16506000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
374000
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
400000
CY2024Q1 nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
84000
CY2024Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
3000
CY2024Q1 nrxp Warrants Issued
WarrantsIssued
1336000
CY2024Q1 us-gaap Cash
Cash
1300000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 nrxp Fractional Stock Issued During Period Shares Reverse Stock Splits
FractionalStockIssuedDuringPeriodSharesReverseStockSplits
0
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the fair value of the convertible note payable, fair value of stock options and warrants, and the utilization of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. </p>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk and Off-Balance Sheet Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Deposits in financial institutions may, from time to time, exceed federally insured limits. As of March 31, 2024 the Company’s cash and cash equivalents balance within money market accounts was in excess of the U.S. federally insured limits by $0.8 million. The Company has not experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy.  </p>
CY2024Q1 nrxp Non Cancellable Contracts
NonCancellableContracts
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Non-cancellable Contracts</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company may record certain obligations as liabilities related to non-cancellable contracts. If appropriate the offsetting costs may be recorded as a deferred cost asset. </p>
CY2024Q1 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
823000
CY2023Q4 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
871000
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
638000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1078000
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
433000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
334000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
128000
CY2024Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
6000
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
6000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2028000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2289000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2766000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2686000
CY2024Q1 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
992000
CY2023Q4 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1112000
CY2024Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
959000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
835000
CY2024Q1 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
579000
CY2023Q4 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
81000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5296000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4714000
CY2024Q1 nrxp Percentage Of Certain Circumstances
PercentageOfCertainCircumstances
0.25
CY2024Q2 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
1
CY2024Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
10
CY2024Q2 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
1
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95700000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95700000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9600000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9600000
CY2024Q1 nrxp Number Of Fractional Shares Issued Related With Reserve Stock Split
NumberOfFractionalSharesIssuedRelatedWithReserveStockSplit
0
CY2024Q1 nrxp Number Of Common Stock Received In Fractional Shares
NumberOfCommonStockReceivedInFractionalShares
1
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
143648
CY2021Q2 us-gaap Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
3792970
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
270000
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
270000
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.80
CY2024Q1 nrxp Warrant Exercisable Term From Date Of Issuance
WarrantExercisableTermFromDateOfIssuance
P6M
CY2024Q1 nrxp Warrant Maturity Term From Date Of Issuance
WarrantMaturityTermFromDateOfIssuance
P5Y
CY2024Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
500000
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3750
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3321499
CY2023 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P3Y10M28D
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
23.01
CY2023Q4 nrxp Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
180000
CY2024Q1 nrxp Class Of Warrant Or Rights Issued
ClassOfWarrantOrRightsIssued
718348
CY2024Q1 nrxp Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
5510
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4034337
CY2024Q1 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P3Y8M4D
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
19.61
CY2024Q1 nrxp Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
807000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
264983
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.30
CY2023 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
75000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
89546
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
175437
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.60
CY2024Q1 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
40000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
105215
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
27.61
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
1000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
300000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M6D
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
242000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
695000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 nrxp Number Of Open Tax Audits
NumberOfOpenTaxAudits
0
CY2022Q4 nrxp Minimum Equity Value Required For Transfer Of Assets
MinimumEquityValueRequiredForTransferOfAssets
50000000
CY2022Q4 nrxp Minimum Equity Required For Transfer Of Assets From Related Party Number Of Consecutive Trading Days
MinimumEquityRequiredForTransferOfAssetsFromRelatedPartyNumberOfConsecutiveTradingDays
20
CY2022Q4 nrxp Minimum Equity Required For Transfer Of Assets From Related Party Number Of Trading Days
MinimumEquityRequiredForTransferOfAssetsFromRelatedPartyNumberOfTradingDays
20
CY2023Q1 nrxp License Agreement Threshold Aggregate Liquidity
LicenseAgreementThresholdAggregateLiquidity
600000
CY2023Q1 nrxp Related Party Transaction Consulting Fee Payable Per Month
RelatedPartyTransactionConsultingFeePayablePerMonth
100000
CY2023Q1 nrxp Related Party Transactions Performance Based Annual Bonus Minimum Target
RelatedPartyTransactionsPerformanceBasedAnnualBonusMinimumTarget
300000
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-008144-index-headers.html Edgar Link pending
0001558370-24-008144-index.html Edgar Link pending
0001558370-24-008144.txt Edgar Link pending
0001558370-24-008144-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrxp-20240331.xsd Edgar Link pending
nrxp-20240331x10q.htm Edgar Link pending
nrxp-20240331x10q001.jpg Edgar Link pending
nrxp-20240331x10q002.jpg Edgar Link pending
nrxp-20240331xex31d1.htm Edgar Link pending
nrxp-20240331xex31d2.htm Edgar Link pending
nrxp-20240331xex32d1.htm Edgar Link pending
nrxp-20240331xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nrxp-20240331_cal.xml Edgar Link unprocessable
nrxp-20240331_def.xml Edgar Link unprocessable
nrxp-20240331_lab.xml Edgar Link unprocessable
nrxp-20240331_pre.xml Edgar Link unprocessable
nrxp-20240331x10q_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending